{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:58:35Z","timestamp":1792612715362,"version":"4.5.0"},"reference-count":50,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"unspecified","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"German Foundation Immunooncology","award":["FA-21-002"],"award-info":[{"award-number":["FA-21-002"]}]},{"name":"Dr. Sepp and Hanne Sturm Memorial Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Verein zur Foerderung des Tumorzentrums der Universitaet Erlangen-Nuernberg e.V.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"German Federal Ministry of Education and Research","award":["01ZX2205E"],"award-info":[{"award-number":["01ZX2205E"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,5,11]]},"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitor-induced immune-related adverse events (irAEs) can be steroid-refractory (sr) or steroid-dependent (sd), requiring second-line therapy. Evidence guiding optimal management of sr\/sd-irAEs while preserving antitumor efficacy is scarce. This study compared extracorporeal photopheresis (ECP) with systemic immunosuppressants (IS) for treatment of sr\/sd-irAEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective two-arm study included 46 patients (23 ECP, 23 IS) with 12 distinct types of irAEs across 6 tumor entities, all classified as steroid-refractory or steroid-dependent. Toxicities affected the gastrointestinal tract, skin, lung, musculoskeletal system, and serosal membranes, with up to seven prior irAE treatment lines. Patients received six cycles of ECP or investigator\u2019s choice IS over 12 weeks. Longitudinal assessments included clinical irAE outcomes, quality of life (QoL), and tumor response. ECP was more frequently used in patients with multi-toxicity (39% vs 9%; p=0.02) and multi-resistance to prior second-line immunosuppression (39% vs 17%; p=0.19).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At week 12, ECP showed a lower cumulative corticosteroid exposure (395\u2009mg vs 1,260\u2009mg prednisolone equivalent; p=0.03), significantly improved QoL (p=0.01), and a numerically higher irAE response rate without statistical significance compared with IS (94% vs 81%; p=0.85). In advanced cutaneous melanoma, ECP was associated with superior overall survival (15 vs 10 months; p=0.02), and longer progression-free survival (9 vs 3 months; p=0.01). No significant safety concerns were observed with ECP; one fatality in the IS group was infection-related.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ECP demonstrated clinical outcomes comparable to IS in sr\/sd-irAEs, with significantly lower cumulative corticosteroid exposure and improved QoL. Furthermore, ECP was associated with a favorable safety profile and showed no evidence of compromised antitumor activity. A multicenter trial is planned for further investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05700565\">NCT05700565<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2026-015185","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T12:10:24Z","timestamp":1781266224000},"page":"e015185","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Extracorporeal photopheresis versus systemic immunosuppression for treatment of immune-related adverse events: clinical outcomes from the prospective two-arm PRIA study"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct05700565","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03601611","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05335928","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04038619","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06470971","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06841705","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04407247","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04797325","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9649-3423","authenticated-orcid":false,"given":"Lisa","family":"Wein","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergology, Ludwig Maximilian University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9487-4363","authenticated-orcid":false,"given":"Carolin","family":"Ertl","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, Ludwig Maximilian University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Ruf","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, Ludwig Maximilian University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Morak","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, Ludwig Maximilian University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, Ludwig Maximilian University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, Ludwig Maximilian University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0037-5283","authenticated-orcid":false,"given":"Xiomara","family":"Garza Vazquez","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, Ludwig Maximilian University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Glatzel","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, Ludwig Maximilian University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"David-Rus","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, Ludwig Maximilian University of Munich, Munich, Germany"},{"name":"Institute of Anthropology Francisc I. Rainer, Romanian Academy, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Mitwalli","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, Ludwig Maximilian University of Munich, Munich, Germany"},{"name":"Division of Dermatology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Srour","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, Ludwig Maximilian University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Sch\u00f6pf","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, Ludwig Maximilian University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Tomsitz","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, Ludwig Maximilian University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars E","family":"French","sequence":"additional","affiliation":[{"name":"Dr. Philip Frost, University of Miami Miller School of Medicine, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-8017","authenticated-orcid":false,"given":"Lucie","family":"Heinzerling","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, Ludwig Maximilian University of Munich, Munich, Germany"},{"name":"Department of Dermatology and Allergology, FAU, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"2026061205101568000_14.6.e015185.1","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1200\/JCO.20.02110","article-title":"Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG\/KEYNOTE-054 Trial","volume":"38","author":"Eggermont","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026061205101568000_14.6.e015185.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30494-0"},{"key":"2026061205101568000_14.6.e015185.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01756-2"},{"key":"2026061205101568000_14.6.e015185.4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2026061205101568000_14.6.e015185.5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15092538","article-title":"Steroid-Refractory Immune-Related Adverse Events Induced by Checkpoint Inhibitors","volume":"15","author":"Tomsitz","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026061205101568000_14.6.e015185.6","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026061205101568000_14.6.e015185.7","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1200\/JCO.24.00191","article-title":"Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials","volume":"42","author":"Verheijden","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026061205101568000_14.6.e015185.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.06.024"},{"key":"2026061205101568000_14.6.e015185.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"2026061205101568000_14.6.e015185.10","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0020"},{"key":"2026061205101568000_14.6.e015185.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001"},{"key":"2026061205101568000_14.6.e015185.12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1499478","article-title":"Impact of steroid-sparing immunosuppressive agents on tumor outcome in the context of cancer immunotherapy with highlight on melanoma: a systematic literature review and meta-analysis","volume":"15","author":"Strouse","year":"2024","journal-title":"Front Immunol"},{"key":"2026061205101568000_14.6.e015185.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006"},{"key":"2026061205101568000_14.6.e015185.14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030546","article-title":"Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"12","author":"Petrelli","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026061205101568000_14.6.e015185.15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3449"},{"key":"2026061205101568000_14.6.e015185.16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2022.08.029","article-title":"Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients\u2019 health-related quality of life","volume":"176","author":"Schulz","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026061205101568000_14.6.e015185.17","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1001\/jamaoncol.2021.0051","article-title":"Chronic Immune-Related Adverse Events Following Adjuvant Anti\u2013PD-1 Therapy for High-risk Resected Melanoma","volume":"7","author":"Patrinely","year":"2021","journal-title":"JAMA Oncol"},{"key":"2026061205101568000_14.6.e015185.18","doi-asserted-by":"crossref","first-page":"113505","DOI":"10.1016\/j.ejca.2023.113505","article-title":"The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects","volume":"199","author":"Ertl","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026061205101568000_14.6.e015185.19","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2018.00236","article-title":"Extracorporeal Photopheresis-An Overview","volume":"5","author":"Cho","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"2026061205101568000_14.6.e015185.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.01.004"},{"key":"2026061205101568000_14.6.e015185.21","doi-asserted-by":"crossref","DOI":"10.1007\/s00011-025-02007-6","article-title":"Extracorporeal photopheresis induces the release of anti-inflammatory fatty acids and oxylipins and suppresses pro-inflammatory sphingosine-1-phosphate","volume":"74","author":"Hagn","year":"2025","journal-title":"Inflamm Res"},{"key":"2026061205101568000_14.6.e015185.22","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1111\/jdv.16890","article-title":"European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 1","volume":"34","author":"Knobler","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026061205101568000_14.6.e015185.23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/jdv.16889","article-title":"European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 - Part 2","volume":"35","author":"Knobler","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026061205101568000_14.6.e015185.24","doi-asserted-by":"crossref","first-page":"115049","DOI":"10.1016\/j.ejca.2024.115049","article-title":"Extracorporeal photopheresis vs. systemic immunosuppression for immune-related adverse events: Interim analysis of a prospective two-arm study","volume":"212","author":"Ertl","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026061205101568000_14.6.e015185.25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Naidoo","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026061205101568000_14.6.e015185.26","unstructured":"U.S. Department of Health and Human Services, National Cancer Institute . Common terminology criteria for adverse events (CTCAE) Version 5.0. National Cancer Institute; 2017."},{"key":"2026061205101568000_14.6.e015185.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2026061205101568000_14.6.e015185.28","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz411"},{"key":"2026061205101568000_14.6.e015185.29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy275"},{"key":"2026061205101568000_14.6.e015185.30","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"2026061205101568000_14.6.e015185.31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003277","article-title":"Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study","volume":"9","author":"Zou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026061205101568000_14.6.e015185.32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011545","article-title":"Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study","volume":"13","author":"Quandt","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026061205101568000_14.6.e015185.33","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1001\/jamaoncol.2022.5041","article-title":"Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma","volume":"8","author":"van Not","year":"2022","journal-title":"JAMA Oncol"},{"key":"2026061205101568000_14.6.e015185.34","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102827","article-title":"Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)","volume":"12","author":"De Giglio","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026061205101568000_14.6.e015185.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198702053160603"},{"key":"2026061205101568000_14.6.e015185.36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006814","article-title":"Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events","volume":"11","author":"Fa\u2019ak","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026061205101568000_14.6.e015185.37","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005111","article-title":"COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis","volume":"10","author":"Holmstroem","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026061205101568000_14.6.e015185.38","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013214","article-title":"JAK inhibitors for the treatment of life-threatening and refractory immune-related adverse events secondary to immune checkpoint inhibitors: a prospective cohort study","volume":"13","author":"Habib","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026061205101568000_14.6.e015185.39","doi-asserted-by":"crossref","first-page":"114028","DOI":"10.1016\/j.ejca.2024.114028","article-title":"Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors","volume":"203","author":"Ruf","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026061205101568000_14.6.e015185.40","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.8118.1","article-title":"Extracoporeal photopheresis treatment of acute graft-versus-host disease following allogeneic haematopoietic stem cell transplantation","volume":"5","author":"Flinn","year":"2016","journal-title":"F1000Res"},{"key":"2026061205101568000_14.6.e015185.41","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1056\/NEJMc1912274","article-title":"Extracorporeal Photopheresis for Colitis Induced by Checkpoint-Inhibitor Therapy","volume":"382","author":"Apostolova","year":"2020","journal-title":"N Engl J Med"},{"key":"2026061205101568000_14.6.e015185.42","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3390\/curroncol31010028","article-title":"Multisystem Immune-Related Adverse Events from Dual-Agent Immunotherapy Use","volume":"31","author":"Li","year":"2024","journal-title":"Curr Oncol"},{"key":"2026061205101568000_14.6.e015185.43","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026061205101568000_14.6.e015185.44","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1470-2045(24)00278-X","article-title":"Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study","volume":"25","author":"Wan","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026061205101568000_14.6.e015185.45","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1007\/s00432-022-04137-4","article-title":"Safety of sequential immune checkpoint inhibitors after prior immune therapy","volume":"149","author":"Awidi","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026061205101568000_14.6.e015185.46","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026061205101568000_14.6.e015185.47","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0755"},{"key":"2026061205101568000_14.6.e015185.48","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026061205101568000_14.6.e015185.49","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.730320","article-title":"Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"2026061205101568000_14.6.e015185.50","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx642"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2026-015185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T12:10:31Z","timestamp":1781266231000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2026-015185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,12]]},"published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1136\/jitc-2026-015185"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2026-015185","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}